INTEGRATION OF IMMUNOTHERAPY INTO ADJUVANT THERAPY FOR RESECTED NSCLC: ALCHEMIST CHEMO-IO (ACCIO)

About this Study
Sponsor Protocol ID:A081801
IRB Number:2021-0643
Actively Enrolling
Interventional
Phase 3
November 20, 2023
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No
Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Dennis Morgan
How to participate in our Clinical Trials